Published in Cell Death Differ on June 01, 2003
Insulin-degrading enzyme (IDE): a novel heat shock-like protein. J Biol Chem (2012) 0.90
Synthesis and anticancer mechanism investigation of dual Hsp27 and tubulin inhibitors. J Med Chem (2013) 0.90
Lead optimization of dual tubulin and Hsp27 inhibitors. Eur J Med Chem (2014) 0.85
The soluble proteome of tobacco Bright Yellow-2 cells undergoing H₂O₂-induced programmed cell death. J Exp Bot (2012) 0.82
Combined magnetic nanoparticle-based microRNA and hyperthermia therapy to enhance apoptosis in brain cancer cells. Small (2014) 0.81
Understanding the role of heat shock protein isoforms in male fertility, aging and apoptosis. World J Mens Health (2014) 0.78
Serum Gp96 is a chaperone of complement-C3 during graft-versus-host disease. JCI Insight (2017) 0.75
Hsp27 negatively regulates cell death by interacting with cytochrome c. Nat Cell Biol (2000) 4.89
Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol (1997) 2.38
Induction of a common pathway of apoptosis by staurosporine. Exp Cell Res (1994) 2.34
HSP27 inhibits cytochrome c-dependent activation of procaspase-9. FASEB J (1999) 2.16
Caspase activation is required for terminal erythroid differentiation. J Exp Med (2001) 1.97
Heat shock proteins: essential proteins for apoptosis regulation. J Cell Mol Med (2008) 1.93
Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia (2010) 1.75
SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias. Leukemia (2013) 1.65
A controlled trial of the tolerance of amphotericin B infused in dextrose or in Intralipid in patients with haematological malignancies. J Antimicrob Chemother (1994) 1.64
Developmental changes in human megakaryopoiesis. J Thromb Haemost (2013) 1.63
Fas ligand-independent, FADD-mediated activation of the Fas death pathway by anticancer drugs. J Biol Chem (1999) 1.60
Diagnostic value of serum IL-6 level in monoclonal gammopathies. Br J Haematol (1995) 1.43
Sensitization of cancer cells treated with cytotoxic drugs to fas-mediated cytotoxicity. J Natl Cancer Inst (1997) 1.38
Lymphoproliferative syndrome with autoimmunity: A possible genetic basis for dominant expression of the clinical manifestations. Blood (1999) 1.38
Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis. Cancer Res (2001) 1.38
Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial. Br J Haematol (2000) 1.37
Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest (1994) 1.34
Heat shock protein 27 enhances the tumorigenicity of immunogenic rat colon carcinoma cell clones. Cancer Res (1998) 1.25
Mutation of the colony-stimulating factor-3 receptor gene is a rare event with poor prognosis in chronic myelomonocytic leukemia. Leukemia (2013) 1.22
JAK2(V617F) negatively regulates p53 stabilization by enhancing MDM2 via La expression in myeloproliferative neoplasms. Oncogene (2011) 1.21
A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression. Leukemia (2013) 1.21
Efficacy and tolerance of an amphotericin B lipid (Intralipid) emulsion in the treatment of candidaemia in neutropenic patients. J Antimicrob Chemother (1993) 1.21
Increase of CD4+ CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+ CD25+ T lymphocytes. Clin Exp Immunol (2007) 1.20
The viral nucleocapsid protein of transmissible gastroenteritis coronavirus (TGEV) is cleaved by caspase-6 and -7 during TGEV-induced apoptosis. J Virol (2000) 1.18
Increased gadd153 messenger RNA level is associated with apoptosis in human leukemic cells treated with etoposide. Cancer Res (1997) 1.16
Mitochondria in hematopoiesis and hematological diseases. Oncogene (2006) 1.11
Cutting edge: the tumor counterattack hypothesis revisited: colon cancer cells do not induce T cell apoptosis via the Fas (CD95, APO-1) pathway. J Immunol (2000) 1.11
Modulation of apoptosis by procaspase-2 short isoform: selective inhibition of chromatin condensation, apoptotic body formation and phosphatidylserine externalization. Oncogene (2001) 1.09
The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors. Leukemia (1995) 1.07
Prophylactic fluconazole and Candida krusei infection. N Engl J Med (1992) 1.07
Resveratrol, a phytochemical inducer of multiple cell death pathways: apoptosis, autophagy and mitotic catastrophe. Curr Med Chem (2011) 1.06
Differential regulation of HSP27 oligomerization in tumor cells grown in vitro and in vivo. Oncogene (2000) 1.05
Interaction of heat-shock protein 90 beta isoform (HSP90 beta) with cellular inhibitor of apoptosis 1 (c-IAP1) is required for cell differentiation. Cell Death Differ (2008) 1.05
Pivotal role of a DEVD-sensitive step in etoposide-induced and Fas-mediated apoptotic pathways. EMBO J (1996) 1.05
Glutathione is implied in the control of 7-ketocholesterol-induced apoptosis, which is associated with radical oxygen species production. FASEB J (1998) 1.03
An evolutionary perspective on chronic myelomonocytic leukemia. Leukemia (2013) 1.03
Cancer cell sensitization to fas-mediated apoptosis by sodium butyrate. Cell Death Differ (1998) 1.02
Selective depletion of inducible HSP70 enhances immunogenicity of rat colon cancer cells. Oncogene (2001) 1.00
Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: results of a randomized trial of the Groupe Ouest-Est Leucémies Aigues Myeloblastiques. J Clin Oncol (2000) 0.99
Upregulation of CASP genes in human tumor cells undergoing etoposide-induced apoptosis. Oncogene (1998) 0.98
Involvement of caspase-2 long isoform in Fas-mediated cell death of human leukemic cells. Blood (2001) 0.98
Identification of tumor-infiltrating macrophages as the killers of tumor cells after immunization in a rat model system. J Immunol (2001) 0.97
Caspase-induced proteolysis of the cyclin-dependent kinase inhibitor p27Kip1 mediates its anti-apoptotic activity. Oncogene (1999) 0.96
Chemotherapy overcomes TRAIL-R4-mediated TRAIL resistance at the DISC level. Cell Death Differ (2010) 0.95
CXCR4 inhibitors selectively eliminate CXCR4-expressing human acute myeloid leukemia cells in NOG mouse model. Cell Death Dis (2012) 0.94
Caspase-2, a novel lipid sensor under the control of sterol regulatory element binding protein 2. Mol Cell Biol (2005) 0.94
Crosstalk between leukemia-associated proteins MOZ and MLL regulates HOX gene expression in human cord blood CD34+ cells. Oncogene (2010) 0.94
Caspase-10 involvement in cytotoxic drug-induced apoptosis of tumor cells. Oncogene (2006) 0.93
Mitochondria-targeting drugs arsenic trioxide and lonidamine bypass the resistance of TPA-differentiated leukemic cells to apoptosis. Blood (2001) 0.92
Cellular localisation of survivin: impact on the prognosis in colorectal cancer. J Cancer Res Clin Oncol (2005) 0.90
p27Kip1 induces drug resistance by preventing apoptosis upstream of cytochrome c release and procaspase-3 activation in leukemic cells. Oncogene (1999) 0.90
Caffeine sensitizes human H358 cell line to p53-mediated apoptosis by inducing mitochondrial translocation and conformational change of BAX protein. J Biol Chem (2001) 0.89
Nonsense-mediated mRNA decay among human caspases: the caspase-2S putative protein is encoded by an extremely short-lived mRNA. Cell Death Differ (2005) 0.89
Activation of the Fas pathway independently of Fas ligand during apoptosis induced by camptothecin in p53 mutant human colon carcinoma cells. Oncogene (2001) 0.87
Identification of a caspase-2 isoform that behaves as an endogenous inhibitor of the caspase cascade. Cancer Res (2000) 0.87
Apoptosis and its modulation in human promyelocytic HL-60 cells treated with DNA topoisomerase I and II inhibitors. Exp Cell Res (1993) 0.87
STAT-1-independent upregulation of FADD and procaspase-3 and -8 in cancer cells treated with cytotoxic drugs. Biochem Biophys Res Commun (1999) 0.86
The transcription factor GATA-1 is overexpressed in breast carcinomas and contributes to survivin upregulation via a promoter polymorphism. Oncogene (2010) 0.86
Bone marrow necrosis and human parvovirus associated infection preceding an Ph1+ acute lymphoblastic leukemia. Leuk Lymphoma (1992) 0.86
Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome. Blood Cancer J (2015) 0.85
Clinical evaluation of a new lipid-based delivery system for intravenous administration of amphotericin B. Eur J Clin Microbiol Infect Dis (1992) 0.85
Fas expression at diagnosis as a biomarker of azacitidine activity in high-risk MDS and secondary AML. Leukemia (2012) 0.85
Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: results of a randomized study. Br J Haematol (1998) 0.84
Thrombocytopenia induced by the histone deacetylase inhibitor abexinostat involves p53-dependent and -independent mechanisms. Cell Death Dis (2013) 0.84
Identification of a functional DNA binding site for the SREBP-1c transcription factor in the first intron of the human caspase-2 gene. Biochim Biophys Acta (2005) 0.84
Bcl-2-mediated inhibition of apoptosis prevents immunogenicity and restores tumorigenicity of spontaneously regressive tumors. J Immunol (1998) 0.83
P27KiP1 overexpression inhibits the growth and doxorubicin sensitivity of HT29 human colon cancer cells in vivo. Anticancer Res (2000) 0.82
Role of tumor cell apoptosis in tumor antigen migration to the draining lymph nodes. J Immunol (2000) 0.82
Contribution of the cyclin-dependent kinase inhibitor p27KIP1 to the confluence-dependent resistance of HT29 human colon carcinoma cells. Int J Cancer (1998) 0.82
Expression of the gadd153 gene in normal and tumor breast tissues by a sensitive RT-PCR method. Int J Mol Med (1999) 0.82
New insights into the kinetic resistance to anticancer agents. Cytotechnology (1998) 0.82
Spontaneous and Fas-induced apoptosis of low-grade MDS erythroid precursors involves the endoplasmic reticulum. Leukemia (2008) 0.81
Der(16)t(1;16)(q10;p10) in multiple myeloma: a new non-random abnormality that is frequently associated with Burkitt's-type translocations. Leukemia (1995) 0.81
BCR-ABL delays apoptosis upstream of procaspase-3 activation. Blood (1998) 0.81
Selective inhibition of apoptosis by TPA-induced differentiation of U937 leukemic cells. Cell Death Differ (1999) 0.81
Evidence for a role of plasticizers in 'eosinophilic' peritonitis in continuous ambulatory peritoneal dialysis. Nephron (1986) 0.80
Stage-dependent activation of cell cycle and apoptosis mechanisms in the right ventricle by pressure overload. Biochim Biophys Acta (2002) 0.80
Dobutamine stress echocardiography identifies anthracycline cardiotoxicity. Eur J Echocardiogr (2000) 0.79
Flt3 ligand lessens the growth of tumors obtained after colon cancer cell injection in rats but does not restore tumor-suppressed dendritic cell function. Int J Cancer (2000) 0.79
Multidrug resistance phenotype evaluation by immunofluorescence and functional tests: comparison of two monoclonal antibodies and three fluorescent dyes in three cells lines. Anticancer Res (1995) 0.79
Polyethylenimine-mediated in vivo gene transfer of a transmembrane superantigen fusion construct inhibits B16 murine melanoma growth. Cancer Gene Ther (2008) 0.79
Effects of cyclosporin at various concentrations on dexamethasone intracellular uptake in multidrug resistant cells. Ann Rheum Dis (2000) 0.78
Systemic lupus erythematosus occurring in a patient with multiple myeloma. Arthritis Rheum (1986) 0.78
Early increase in DcR2 expression and late activation of caspases in the platelet storage lesion. Leukemia (2001) 0.78
High concentrations of intrathecal interleukin-6 in human bacterial and nonbacterial meningitis. J Infect Dis (1992) 0.78
Quinine improves results of intensive chemotherapy (IC) in myelodysplastic syndromes (MDS) expressing P-glycoprotein (PGP). Updated results of a randomized study. Groupe Français des Myélodysplasies (GFM) and Groupe GOELAMS. Adv Exp Med Biol (1999) 0.78
PreB1 (CD10-) acute lymphoblastic leukemia: immunophenotypic and genomic characteristics, clinical features and outcome in 38 adults and 26 children. The Groupe dEtude Immunologique des Leucémies. Leuk Lymphoma (1998) 0.78
Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium. Blood Cancer J (2011) 0.77
Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon alpha-2b for the treatment of chronic myelogenous leukemia patients in chronic phase. Leukemia (2002) 0.77
Cinchonine per os: efficient circumvention of P-glycoprotein-mediated multidrug resistance. Anticancer Drug Des (1995) 0.77
Comparative effects of quinine and cinchonine in reversing multidrug resistance on human leukemic cell line K562/ADM. Leukemia (1994) 0.77
FAS(CD95) ligand expression by tumor cell variants can be unrelated to their capacity to induce tolerance or immune rejection. Int J Cancer (1999) 0.76
Infraclinical neuropathies related to immunodeficiency virus infection associated with higher T-helper cell count. J Acquir Immune Defic Syndr (1989) 0.76
[Trefoil factor family gene and peptide expression in pterygium]. J Fr Ophtalmol (2003) 0.76
Immune mechanisms in HIV-related neuropathies. Lancet (1989) 0.75
Potential usefulness of quinine to circumvent the anthracycline resistance in clinical practice. Br J Cancer (1990) 0.75
Intracellular redistribution of procaspases during TPA-induced differentiation of U937 human leukemic cells. Leukemia (2002) 0.75
[Invasive pulmonary aspergillosis in neutropenic patients. Analysis of a series of 36 cases: contribution of thoracic scanners and itraconazole]. Ann Med Interne (Paris) (1995) 0.75